Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date

Mohamad Moussa1 Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon

Athanasios Papatsoris2 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, GreeceCorrespondence[email protected]

Mohamed Abou Chakra1 Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon

Athanasios Dellis2 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece;3 Department of Surgery, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece

Abstract

Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profile in heavily pretreated patients with locally advanced or metastatic urothelial carcinoma. Early survival reports demonstrate a significant antitumor effectiveness along with a rather acceptable safety profile in a difficult-to-treat population.

Keywords:

Disclosure

The authors report no conflicts of interest in this work.

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date

Information for

Open access

Opportunities

Help and information

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date

Abstract

Disclosure

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature